research group

Metabolic syndrome and its complications

Main research area of the group

Internal Medicine, Endocrinology, Reproductive Medicine Complex and personalized scientific, preventive and therapeutic approach to metabolic
syndrome and its complications, as a medical issue with the growing importance of social impact.

Leading researcher:

Prof. Zdravko Asenov Kamenov, MD, PhD, DMSc

Department of Internal Medicine, MU – Sofia

Members of the research team:

  • Assoc. Prof. Antoaneta Trifonova Gateva, PhD (DMSc);
  • Assoc. Prof. Vera Nacheva Karamfilova, PhD;
  • Yavor Sahov Assyov, PhD;
  • Emanuela Tsvetkova Zaharieva, PhD;
  • Tsvetan Vladimirov Gatev – PhD student;
  • Antonina Gerganova – PhD student;
  • Savelia Gandeva – PhD student;
  • Diana Nikolova – PhD student;
  • Dobrin Popov – young researcher;
  • Yuliyan Naydenov – young researcher

Research goals

This project aims to develop strategies for a complex and personalized, preventive and therapeutic approach in patients with metabolic syndrome utilizing instrumental, biochemical and genetic tests and the implementation of new biomarkers.

The goal of the research project is to assess strategies to reduce the global and social impact of metabolic syndrome (MS). Given that epidemiological data suggest that we are in а growing metabolic syndrome pandemic, we aim to reduce the health and social burden of MS. In accordance with this our aims are:

  • To conduct a complex cross-sectional evaluation of patients with metabolic syndrome with regard to genetic variations, body composition and muscle strength, metabolic disturbances (obesity, carbohydrate disturbances, hypertension, dyslipidemia), micro- and macrovascular complications (neuropathy, retinopathy, nephropathy and atherosclerotic changes)
  • To create a Database, Biobank and Genetic bank with detailed information and materials for future evaluation
  • To evaluate the link between the complications of metabolic syndrome and certain biochemical and genetic characteristics of the patients. This will allow for identification of novel biomarkers and genetic markers for increased metabolic and cardiovascular risk and for more individualized approach to patients with metabolic syndrome in terms of risk evaluation and complications prevention